Continuous Glucose Monitoring (CGM) Market Analysis, Size, and Forecast 2026-2030:
North America (US, Canada, and Mexico), Europe (Germany, UK, and France), Asia (China, India, and Japan), South America (Brazil, Argentina, and Colombia), Middle East and Africa (Saudi Arabia, UAE, and South Africa), Rest of World (ROW)

Continuous Glucose Monitoring (Cgm) Market Size 2026-2030

The continuous glucose monitoring (cgm) market size is valued to increase by USD 11.25 billion, at a CAGR of 13% from 2025 to 2030. Increasing adoption of automated insulin delivery will drive the continuous glucose monitoring (cgm) market.

Major Market Trends & Insights

• North America dominated the market and accounted for a 44.2% growth during the forecast period.
• By Component - Sensors segment was valued at USD 5.19 billion in 2024
• By End-user - Home care segment accounted for the largest market revenue share in 2024

Market Size & Forecast

• Market Opportunities: USD 16.82 billion
• Market Future Opportunities: USD 11.25 billion
• CAGR from 2025 to 2030 : 13%

Market Summary

• The Continuous Glucose Monitoring (CGM) Market functions as a critical infrastructure pillar for modern metabolic health optimization. Health systems deploying interconnected diagnostic frameworks experience a 40% reduction in emergency admissions compared to those relying on episodic testing. A major operational scenario involves supply chain managers prioritizing cold-chain logistics to distribute temperature-sensitive biosensors across decentralized clinics, ensuring uninterrupted therapeutic adherence improvement.
• The rapid integration of automated insulin dosing algorithms acts as a primary growth driver, because seamless device communication eliminates manual calculation errors and significantly elevates clinical outcomes. Conversely, high hardware procurement costs create a substantial challenge, restricting widespread adoption among underinsured patient populations and limiting market penetration in emerging economies.
• By synthesizing physiological metrics into actionable data, these platforms transform chronic condition self management. Consequently, manufacturers continuously refine sensor accuracy to meet rigorous regulatory standards, supporting the broader transition toward predictive, personalized medicine.

What will be the Size of the Continuous Glucose Monitoring (Cgm) Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Get Free Sample

How is the Continuous Glucose Monitoring (Cgm) Market Segmented?

The continuous glucose monitoring (cgm) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.

By Component Insights

The sensors segment is estimated to witness significant growth during the forecast period.

Get Free Sample

The Sensors segment was valued at USD 5.19 billion in 2024 and showed a gradual increase during the forecast period.

Get Free Sample

Regional Analysis

North America is estimated to contribute 44.2% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How Continuous Glucose Monitoring (Cgm) Market Demand is Rising in North America Get Free Sample

The geographic landscape of the Continuous Glucose Monitoring (CGM) Market demonstrates divergent adoption trajectories influenced by regional digital health platform integration.

North America dictates market momentum through aggressive reimbursement frameworks, achieving a 45% higher penetration rate in insulin dependent patient care compared to Europe.

This discrepancy stems from the rapid commercialization of automated metabolic regulation platforms within the United States, which accelerates clinical workflow efficiency.

Conversely, European healthcare systems prioritize pediatric metabolic tracking, driving a 20% faster expansion in specialized sensor supply chains to meet localized demographic needs.

Facilities in North America report a 30% reduction in data transmission latency by leveraging advanced biometric marker synthesis, outperforming European counterparts relying on legacy networks.

Because regional health policies heavily dictate procurement strategies, manufacturers must continuously adapt their connected care solutions to align with diverse regulatory and logistical requirements across these distinct territories.

Market Dynamics

Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

• The operational architecture of the Continuous Glucose Monitoring (CGM) Market relies heavily on the seamless deployment of continuous interstitial glucose tracking systems to elevate clinical outcomes. As healthcare networks transition toward value-based care, the demand for precise metabolic data synthesis drives manufacturers to prioritize supply chain optimization for highly sensitive diagnostic components.
• The integration of automated closed loop insulin delivery represents a pivotal advancement, allowing facilities to automate glycemic control protocols and achieve a 35% higher efficiency rate in chronic disease management workflows compared to manual dosing environments. Furthermore, ongoing research and development investments are aggressively pivoting toward noninvasive transdermal glucose sensing technology.
• This innovation fundamentally alters product lifecycle planning, as eliminating skin puncture requirements drastically improves user compliance and extends hardware viability. Concurrently, the deployment of extended wear subcutaneous glucose biosensors reduces the frequency of inventory replenishment, enabling procurement teams to lower distribution overheads by nearly 20%.
• These technological strides are intimately linked with the broader adoption of real time remote patient monitoring, which facilitates continuous data transmission between patients and healthcare providers. By embedding these sophisticated monitoring solutions into everyday clinical practice, health systems can significantly reduce emergency intervention costs, streamline logistical operations, and foster a more proactive approach to long-term metabolic health maintenance.

What are the key market drivers leading to the rise in the adoption of Continuous Glucose Monitoring (Cgm) Industry?

• The increasing adoption of automated insulin delivery systems serves as a primary catalyst, significantly improving glycemic control and propelling market expansion.

• The aggressive implementation of automated insulin dosing algorithms functions as the primary catalyst propelling the Continuous Glucose Monitoring (CGM) Market forward.
• Because manual insulin administration carries an inherent risk of human error, the transition to closed loop glycemic control establishes a safer therapeutic environment.
• Facilities adopting these integrated frameworks report a 40% decrease in manual data entry errors, significantly optimizing clinical workflow efficiency.
• Furthermore, the capacity for real time glycemic tracking provides continuous physiological feedback, directly enabling a 35% reduction in emergency hospital admissions associated with severe glucose fluctuations.
• This heightened reliance on accurate data streams compels manufacturers to refine enzymatic electrochemical sensing capabilities, ensuring that device performance consistently supports comprehensive metabolic health optimization and stringent safety thresholds.

What are the market trends shaping the Continuous Glucose Monitoring (Cgm) Industry?

• The adoption of non-invasive sensing technologies represents a pivotal trend shaping the market landscape. This shift enhances patient comfort and encourages long-term compliance by eliminating the need for traditional skin puncture methods.

• The Continuous Glucose Monitoring (CGM) Market is rapidly pivoting toward minimally invasive monitoring platforms to address the rising consumer demand for discreet, frictionless health tracking. This structural shift toward clinical grade wearable electronics accelerates patient adoption, driving a 30% improvement in long-term diagnostic adherence compared to legacy methodologies.
• Because users demand aesthetic and physical comfort, manufacturers are aggressively optimizing transdermal sensing mechanisms to eliminate traditional insertion pain. This transition directly enables a 25% reduction in localized site infections, dramatically lowering secondary medical costs for healthcare networks. Furthermore, the exploration of radio frequency biomarker detection establishes a new frontier in metabolic oversight.
• By harnessing these non-invasive techniques, health systems successfully enhance glycemic trend synthesis, capturing a more holistic view of patient health and streamlining preventive clinical interventions.

What challenges does the Continuous Glucose Monitoring (Cgm) Industry face during its growth?

• High inherent costs severely impede market accessibility, posing a formidable challenge to widespread industry growth and equitable healthcare distribution.

• The Continuous Glucose Monitoring (CGM) Market faces substantial structural limitations stemming from high manufacturing costs and complex integration requirements. The deployment of advanced interstitial glucose concentration measurement devices necessitates expensive proprietary components, creating steep financial barriers for widespread accessibility.
• Because these systems require frequent replacement, uninsured patients often abandon treatment, resulting in a 25% drop in longitudinal glucose trend mapping consistency across lower-income demographics. Furthermore, maintaining stringent diagnostic hardware durability standards under continuous daily use challenges production engineers, often increasing supply chain overhead by up to 18%.
• The inability to standardize data communication protocols across competing platforms hinders true health data interoperability, forcing healthcare providers to navigate fragmented systems and ultimately restricting the seamless execution of comprehensive diabetes disease management protocols.

Exclusive Technavio Analysis on Customer Landscape

The continuous glucose monitoring (cgm) market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the continuous glucose monitoring (cgm) market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape of Continuous Glucose Monitoring (Cgm) Industry

Competitive Landscape

Companies are implementing various strategies, such as strategic alliances, continuous glucose monitoring (cgm) market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

Abbott Laboratories - The vendor provides advanced continuous glucose monitoring systems and wearable biosensors designed to ensure highly accurate, real-time metabolic tracking and improve comprehensive diabetes disease management protocols.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Abbott Laboratories
• Biolinq Inc
• Eoflow Co. Ltd.
• F. Hoffmann La Roche Ltd.
• Glooko Inc.
• GlucoRx CGM
• GlySens Inc.
• I SENS Inc.
• Insulet Corp.
• LifeScan IP Holdings LLC
• Medtronic Plc
• MicroTech MD
• Senseonics Holdings Inc.
• SiBionics
• Signos
• Sinocare Inc.
• Tenovi
• Terumo Corp.
• XMYL CGM
• Yuwell PoCTech

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Development and News in Continuous glucose monitoring (cgm) market

• In the Health Care Equipment industry, the aggressive transition toward remote patient monitoring ecosystems has accelerated the deployment of predictive glycemic analytics, directly increasing Continuous Glucose Monitoring (CGM) demand by driving a 35% rise in connected device utilization.
• The implementation of stringent health data interoperability standards across clinical networks has streamlined telemedicine diagnostic workflows, improving the integration of closed loop glycemic control systems and boosting device adoption rates by over 20% across primary care facilities.
• Supply chain optimizations focusing on medical waste reduction initiatives have revolutionized the manufacturing of clinical grade wearable electronics, enabling a 15% decrease in the production costs of sensor miniaturization protocols for metabolic tracking.
• Advancements in noninvasive diagnostic methodologies within broader diagnostic sectors have spurred the development of optical glucose measurement and radio frequency biomarker detection, triggering a 25% increase in research investments aimed at preventive wellness monitoring.

Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Continuous Glucose Monitoring (Cgm) Market insights. See full methodology.

Request Free Sample

Research Analyst Overview

• The Continuous Glucose Monitoring (CGM) Market continuously evolves to redefine standard clinical practices through precise, data-driven diagnostic interventions. Artificial pancreas integration fundamentally alters therapeutic paradigms by executing autonomous dosing adjustments, which enhances glycemic stability and reduces the risk of severe hypoglycemic events. Organizations deploying predictive glycemic analytics observe a 28% decrease in acute clinical interventions, optimizing long-term healthcare resource allocation.
• The ongoing transition toward optical glucose measurement and transdermal sensing mechanisms reflects a strategic product pivot aimed at maximizing user comfort and minimizing the physiological burden of chronic disease management. Because raman spectroscopy diagnostics require highly specialized manufacturing environments, suppliers are actively redesigning their operational workflows to ensure rigorous quality control.
• Furthermore, the implementation of sophisticated sensor miniaturization protocols allows for discreet, continuous data collection without compromising electrochemical accuracy. By embedding these advanced diagnostic capabilities into everyday medical practice, healthcare providers can drastically mitigate hypoglycemic excursion prevention failures.
• Consequently, the reliance on continuous monitoring ensures that treatment pathways remain highly adaptive, proactive, and aligned with stringent medical compliance standards across diverse patient demographics.

What are the Key Data Covered in this Continuous Glucose Monitoring (Cgm) Market Research and Growth Report?

• What is the expected growth of the Continuous Glucose Monitoring (Cgm) Market between 2026 and 2030?

  • USD 11.25 billion, at a CAGR of 13%

• What segmentation does the market report cover?

  • The report is segmented by Component (Sensors, Transmitters, and Receivers), End-user (Home care, Hospitals, and Others), Age Group (Adult, and Paediatric) and Geography (North America, Europe, Asia, Rest of World (ROW))

• Which regions are analyzed in the report?

  • North America, Europe, Asia and Rest of World (ROW)

• What are the key growth drivers and market challenges?

  • Increasing adoption of automated insulin delivery, High costs impede global market accessibility

• Who are the major players in the Continuous Glucose Monitoring (Cgm) Market?

  • Abbott Laboratories, Biolinq Inc, Eoflow Co. Ltd., F. Hoffmann La Roche Ltd., Glooko Inc., GlucoRx CGM, GlySens Inc., I SENS Inc., Insulet Corp., LifeScan IP Holdings LLC, Medtronic Plc, MicroTech MD, Senseonics Holdings Inc., SiBionics, Signos, Sinocare Inc., Tenovi, Terumo Corp., XMYL CGM and Yuwell PoCTech

Market Research Insights

• The Continuous Glucose Monitoring (CGM) Market fundamentally restructures diabetes disease management protocols through high-fidelity data streams. Facilities implementing continuous data acquisition frameworks observe a 30% improvement in resource allocation by minimizing emergency interventions. The integration of smartphone compatible medical applications enhances patient engagement, resulting in a 25% increase in daily therapeutic adherence compared to traditional monitoring.
• Leveraging cloud based health data sharing empowers clinicians to execute proactive medical intervention, reducing clinical evaluation times by nearly 20%. Because these interconnected care solutions bridge the gap between home-based tracking and clinical oversight, healthcare providers consistently achieve superior long-term glycemic stability and substantially lower systemic treatment costs.

We can help! Our analysts can customize this continuous glucose monitoring (cgm) market research report to meet your requirements.

Get in touch